Streetbeat News

ENVB

Enveric Biosciences, Inc.

https://www.enveric.com

Industry

Biotechnology

Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Open

1.69

Mkt cap

3.3M

Volume

79K

High

1.78

P/E Ratio

-0.05

52-wk high

420.75

Low

1.64

Div yield

N/A

52-wk low

1.13

Enveric Biosciences' CEO, Joseph Tucker, issued a letter to shareholders updating them on the company's development program and recent events. Enveric focuses on developing neuroplastogenic small-molecule therapeutics for anxiety, depression, and addiction disorders.

Portfolio Pulse from

February 27, 2025 | 2:45 pm

Enveric Biosciences has closed a $5 million public offering, issuing 1,666,666 shares of common stock and Series A warrants. The company focuses on developing therapeutics for anxiety, depression, and addiction disorders.

Portfolio Pulse from

February 03, 2025 | 10:15 pm

Enveric Biosciences has received a Notice of Allowance from the USPTO for a patent application related to its EVM301 Series of molecules, which are being developed for treating depression, anxiety, and addiction disorders.

Portfolio Pulse from

January 30, 2025 | 9:15 pm

Several healthcare stocks experienced significant price movements in Wednesday's after-market session. CNS Pharma, DBV Technologies, and Molina Healthcare were among the gainers, while Enveric Biosciences and Evotec saw declines. Molina Healthcare's rise is linked to its Q3 earnings release.

Portfolio Pulse from Benzinga Insights

October 23, 2024 | 8:31 pm

Enveric Biosciences (NASDAQ:ENVB) announced positive preclinical results for its lead drug candidate, EB-003, which targets serotonergic receptors without causing hallucinations. The drug shows potential for treating mental health conditions like depression and anxiety, with minimal cardiovascular and CNS risks. Enveric plans further testing and aims to start clinical development by the end of 2025.

Portfolio Pulse from Juan Spínelli

October 15, 2024 | 3:27 pm

In Tuesday's pre-market session, several healthcare stocks experienced significant movements. Gainers included Gritstone Bio, Hoth Therapeutics, Lipella Pharmaceuticals, Enveric Biosciences, Oncternal Therapeutics, and Chemomab Therapeutics. Losers included Virpax Pharmaceuticals, Burning Rock Biotech, Mainz Biomed, CareDx, Inventiva, and Novo Integrated Sciences.

Portfolio Pulse from Benzinga Insights

October 15, 2024 | 12:08 pm

Enveric Biosciences has released pharmacology and safety data for its compound EB-003, which has shown the ability to target desired serotonergic receptors in vitro.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 12:06 pm

Companies like Mindstate Design Labs and Atai Life Sciences are developing new forms of psychedelics, termed Psychedelics 2.0, to offer mental health benefits with fewer risks. These innovations aim to address the challenges of traditional psychedelics, such as side effects and intensive monitoring requirements. Enveric Biosciences is exploring non-hallucinogenic psychedelics, potentially offering antidepressant-like benefits without extensive clinical sessions.

Portfolio Pulse from Juan Spínelli

October 04, 2024 | 7:39 pm

Enveric Biosciences presented data on its lead candidate, EB-003, at a pharmacology workshop. EB-003 shows potential as a non-hallucinogenic treatment for depression and anxiety, setting it apart from other DMT analogs.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 12:42 pm

Enveric Biosciences (NASDAQ:ENVB) has presented promising preclinical research on its non-hallucinogenic psychedelic compound, EB-003, for treating anxiety and depression. The company plans to file an IND application by Q3 2025 and start clinical trials by the end of 2025.

Portfolio Pulse from Jelena Martinovic

September 25, 2024 | 12:30 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.